Pharmaxis short-listed for Prix Galien UK award
30 June, 2014 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) and seven multinational biotechs with a presence in Australia have been short-listed for the Prix Galien UK pharmaceutical R&D awards.
Admedus expects $9m in income for FY13-14
27 June, 2014 by Dylan Bushell-EmblingAdmedus (ASX:AHZ) made good progress with the commercialisation of CardioCel during the financial year and hopes to report the results of its subsidiary's HSV-2 trial next quarter.
Anatara seeking partners as LSQ finds one
27 June, 2014 by Dylan Bushell-EmblingAnatara Lifesciences used BIO 2014 to seek partners for a non-antibiotic diarrhoea treatment, while Life Sciences Queensland has signed an MoU with biotech accelerator Bioindustrial Innovation Canada.
Entrepreneurs' Infrastructure Programme seeks comment
26 June, 2014AusBiotech has made preliminary comment regarding the establishment of the Entrepreneurs' Infrastructure Programme (EIP), based on questions posed in the EIP Discussion Paper (June 2014).
pSivida licensee gets Italian approval for Iluvien
25 June, 2014pSivida (ASX:PVA) has revealed its licensee Alimera Sciences has secured Class C approval in Italy for diabetic macular oedema treatment Iluvien.
Mesoblast MPCs improve outcomes in heart failure
25 June, 2014Mesoblast's (ASX:MSB) mesenchymal precursor cells were associated with improved outcomes in end-stage heart failure patients needing to be weaned off LVADs during a recent trial.
Industry input to shape new medical technology strategy for Victoria
24 June, 2014The Victorian Government has announced the development of a new strategy to position Victoria as an internationally competitive developer of medical technology (medtech), while also providing new opportunities for the state's advanced manufacturing sector.
Bionomics licenses BNC375 for up to $558m
24 June, 2014 by Dylan Bushell-EmblingBionomics (ASX:BNO) has signed a research collaboration and licensing deal with Merck covering BNC375, a treatment candidate for Alzheimer's and other CNS conditions.
Biotech student to showcase research in AbbVie Student Poster Awards
19 June, 2014The AusBiotech 2014 national conference will feature a student poster display in the main exhibition hall for the duration of the conference, and the national winner of the AbbVie Student Poster Awards.
Mesoblast's MPCs show promise in type 2 diabetes
19 June, 2014 by Dylan Bushell-EmblingMesoblast (ASX:MSB) revealed its MPCs were able to improve glycaemic control during a phase II trial in type 2 diabetes.
Australia needs tax incentives to be globally competitive
17 June, 2014AusBiotech has submitted to the Competition Policy Review (June 2014) that Australia needs to complement the R&D Tax Incentive with the Australian Innovation and Manufacturing (AIM) Incentive if it is to remain competitive and relevant on the world stage.
Osprey gets FDA clearance for second-gen AVERT
17 June, 2014 by Dylan Bushell-EmblingOsprey Medical (ASX:OSP) has secured FDA 510(k) approval for the improved version of its AVERT system, designed to reduce the risk of kidney damage from the dyes used in heart procedures.
Ortho-ATI shows promise in hip tendon pain
16 June, 2014 by Dylan Bushell-EmblingOrthocell has presented results of a successful pilot trial of regenerative therapy Ortho-ATI in 12 patients with gluteal tendinopathy.
GI Dynamics presents EndoBarrier research
16 June, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has presented more research into the effectiveness of - and mechanism of action behind - EndoBarrier, its non-surgical device therapy for obesity and type 2 diabetes.
Starpharma completes chairman succession
16 June, 2014 by Dylan Bushell-EmblingRob Thomas has formally taken over from Peter Bartels as chairman of Starpharma (ASX:SPL) following a seven-month transition period.
